

Date: February 23, 2026

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations)**

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we hereby inform that the Company has executed on February 23, 2026, a First Amendment to the Loan Agreement dated April 15, 2024 entered into with Neoanthem Lifesciences Private Limited (“Neoanthem”), a wholly owned subsidiary of the Company.

The background of the transaction is summarized below:

Pursuant to the approval of the Board of Directors on March 14, 2024, the Company had entered into a Loan Agreement dated April 15, 2024 (the “Original Loan Agreement”) for provision of financial assistance of up to Rs. 300,00,00,000 (Rupees Three Hundred Crores Only) to Neoanthem Lifesciences Private Limited, including an option to convert up to Rs. 100,00,00,000 (Rupees One Hundred Crores Only) into equity shares. The overall financial assistance limit was subsequently enhanced to Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores) pursuant to a Board Resolution dated June 27, 2024. In accordance with the terms of the Original Loan Agreement and upon obtaining the requisite approvals from the Board and Shareholders of Neoanthem, Rs. 100,00,00,000 (Rupees One Hundred Crores Only) was converted into equity shares on February 21, 2025.

Pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in connection with the proposed listing of the Company, the requisite approvals of the Audit Committee and the Board of Directors were obtained on June 9, 2025. Further, the transaction being a material related party transaction, approval of the Shareholders was also obtained at the Annual General Meeting held on June 10, 2025.

Further, at its meeting held on November 8, 2025, the Board approved the conversion of an additional amount of Rs 275,00,00,000 (Rupees Two Hundred and Seventy Five Crores Only) of the loan into equity which has been formalised pursuant to the First Amendment Agreement dated February 23, 2026.

The aforementioned amendment is material in terms of “the Policy on Determination of Materiality for Disclosure of Events or Information”.

The details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is attached herewith as “Annexure –A”

The above intimation is also available on the Company’s website at <https://www.anthembio.com/investor>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

*(Formerly known as Anthem Biosciences Private Limited)*

---

**Divya Prasad**  
**Company Secretary & Compliance Officer**  
**Membership No: A41438**

## Annexure A

Sr No.	Particulars	Details
1	Name(s) of parties with whom the agreement is entered;	Anthem Biosciences Limited and Neoanthem Lifesciences Private Limited (wholly owned subsidiary)
2	Purpose of entering into the agreement;	The First Amendment Agreement has been entered into to convert an additional amount of up to Rs 275,00,00,000 (Rupees Two Hundred and Seventy Five Crores Only) of the loan into equity shares of Neoanthem, within the overall sanctioned financial assistance limit of Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores).
3	Size of agreement	Overall sanctioned financial assistance limit of up to Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores) pursuant to the Board Resolution passed on June 27, 2024 and the First Amendment Agreement.
4	Shareholding, if any, in the entity with whom the agreement is executed;	The Company holds 100% of the equity shares of Neoanthem.
5	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	<p>(i) The Company has sanctioned financial assistance of up to Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores) to Neoanthem Lifesciences Private Limited pursuant to the Board Resolution dated June 27, 2024.</p> <p>(ii) The original terms as per the Original Loan Agreement included an option to convert up to Rs. 100,00,00,000 (Rupees Hundred Crore Only) of the financial assistance into equity shares of Neoanthem, which was exercised on February 21, 2025.</p> <p>(iii) Pursuant to the First Amendment Agreement, the Company has been granted an option to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only), out of the sanctioned financial assistance limit, into fully paid-up equity shares of Neoanthem, at its discretion and subject to applicable approvals at the time of conversion.</p> <p>(iv) The financial assistance is in the nature of an unsecured loan.</p> <p>(v) The loan carries interest as per the terms mutually agreed between the parties under the Loan Agreement.</p>
6	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	Neoanthem Lifesciences Private Limited is a wholly owned subsidiary of the Company and forms part of the Company's group structure.

Sr No.	Particulars	Details																								
		Mr. Ajay Bhardwaj, Managing Director, Mr. Ganesh Sambasivam, Whole-time Director, and Mr. K. C. Ravindra, Whole-time Director of the Company, are also on the Board of Neoanthem.																								
7	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	<p>Yes, the transaction qualifies as a Material Related Party Transaction under the Companies Act, 2013 and SEBI LODR Regulations, 2015.</p> <p>The Company in its Audit Committee and the Board Meeting held on June 09, 2025 and the Shareholders Meeting held on June 10, 2025 approved the said related party transaction.</p> <p>The transaction is undertaken on an arm’s length basis.</p>																								
8	In case of issuance of shares to the parties, details of issue price, class of shares issued	At the discretion of the Company, the loan amount of Rs. 275,00,00,000 (Rupees Two Hundred and Seventy Five Crores Only), be converted into fully paid up equity shares of Neoanthem at a value determined in accordance with applicable law and based on valuation report provided by the registered valuer at the time of allotment.																								
9	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	<table border="1"> <thead> <tr> <th data-bbox="659 981 735 1057">Sl No</th> <th data-bbox="735 981 911 1057">Particulars</th> <th data-bbox="911 981 1361 1057">Response</th> </tr> </thead> <tbody> <tr> <td data-bbox="659 1057 735 1099">1</td> <td data-bbox="735 1057 911 1099">Lender</td> <td data-bbox="911 1057 1361 1099">Anthem Biosciences Limited</td> </tr> <tr> <td data-bbox="659 1099 735 1176">2</td> <td data-bbox="735 1099 911 1176">Borrower</td> <td data-bbox="911 1099 1361 1176">Neoanthem Lifesciences Private Limited</td> </tr> <tr> <td data-bbox="659 1176 735 1254">3</td> <td data-bbox="735 1176 911 1254">Nature of Loan</td> <td data-bbox="911 1176 1361 1254">Unsecured Loan</td> </tr> <tr> <td data-bbox="659 1254 735 1413">4</td> <td data-bbox="735 1254 911 1413">Amount of Loan</td> <td data-bbox="911 1254 1361 1413">The financial assistance limit not exceeding Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores).</td> </tr> <tr> <td data-bbox="659 1413 735 1608">5</td> <td data-bbox="735 1413 911 1608">Date of Execution of First Amendment Agreement</td> <td data-bbox="911 1413 1361 1608">February 23, 2026</td> </tr> <tr> <td data-bbox="659 1608 735 1727">6</td> <td data-bbox="735 1608 911 1727">Security Provided, if any</td> <td data-bbox="911 1608 1361 1727">Not applicable as it is an Unsecured Loan</td> </tr> <tr> <td data-bbox="659 1727 735 1933">7</td> <td data-bbox="735 1727 911 1933">Amount of Loan Outstanding as on date of disclosure</td> <td data-bbox="911 1727 1361 1933">Rs 439.41 Crores</td> </tr> </tbody> </table>	Sl No	Particulars	Response	1	Lender	Anthem Biosciences Limited	2	Borrower	Neoanthem Lifesciences Private Limited	3	Nature of Loan	Unsecured Loan	4	Amount of Loan	The financial assistance limit not exceeding Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores).	5	Date of Execution of First Amendment Agreement	February 23, 2026	6	Security Provided, if any	Not applicable as it is an Unsecured Loan	7	Amount of Loan Outstanding as on date of disclosure	Rs 439.41 Crores
Sl No	Particulars	Response																								
1	Lender	Anthem Biosciences Limited																								
2	Borrower	Neoanthem Lifesciences Private Limited																								
3	Nature of Loan	Unsecured Loan																								
4	Amount of Loan	The financial assistance limit not exceeding Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores).																								
5	Date of Execution of First Amendment Agreement	February 23, 2026																								
6	Security Provided, if any	Not applicable as it is an Unsecured Loan																								
7	Amount of Loan Outstanding as on date of disclosure	Rs 439.41 Crores																								
10	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest	No nominee director has been appointed pursuant to the said agreement. No conflict of interest arises other than the related party relationship disclosed above																								

Sr No.	Particulars	Details																		
	arising out of such agreements, etc.;																			
11	<p>In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):</p> <ol style="list-style-type: none"> <li>Name of the Parties to the agreement</li> <li>Nature of the agreement</li> <li>Date of execution of agreement</li> <li>Details of amendments and impact thereof or reason for termination and impact thereof.</li> </ol>	<p>Disclosure of additional details pursuant to the First Amendment Agreement, for submission to the stock exchange:</p> <table border="1" data-bbox="667 416 1361 2098"> <thead> <tr> <th data-bbox="667 416 743 495">Sl No</th> <th data-bbox="743 416 1023 495">Particulars</th> <th data-bbox="1023 416 1361 495">Response</th> </tr> </thead> <tbody> <tr> <td data-bbox="667 495 743 651">1</td> <td data-bbox="743 495 1023 651">Name of the Parties to the agreement</td> <td data-bbox="1023 495 1361 651">The First Amendment to the Loan Agreement is between the Company and Neoanthem.</td> </tr> <tr> <td data-bbox="667 651 743 1003">2</td> <td data-bbox="743 651 1023 1003">Nature of the agreement</td> <td data-bbox="1023 651 1361 1003">The First Amendment Agreement has been executed to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem.</td> </tr> <tr> <td data-bbox="667 1003 743 1122">3a</td> <td data-bbox="743 1003 1023 1122">Date of Execution of Original Loan Agreement</td> <td data-bbox="1023 1003 1361 1122">April 15, 2024</td> </tr> <tr> <td data-bbox="667 1122 743 1240">3b</td> <td data-bbox="743 1122 1023 1240">Date of Execution of First Amendment Agreement</td> <td data-bbox="1023 1122 1361 1240">February 23, 2026</td> </tr> <tr> <td data-bbox="667 1240 743 2098">4</td> <td data-bbox="743 1240 1023 2098">Details of amendments and impact thereof or reason for termination and impact thereof</td> <td data-bbox="1023 1240 1361 2098">The Board of Directors approved the First Amendment Agreement to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem, which is within the overall sanctioned financial assistance limit of Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores), at the discretion of the Company and subject to applicable approvals at a value determined in accordance with applicable law and</td> </tr> </tbody> </table>	Sl No	Particulars	Response	1	Name of the Parties to the agreement	The First Amendment to the Loan Agreement is between the Company and Neoanthem.	2	Nature of the agreement	The First Amendment Agreement has been executed to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem.	3a	Date of Execution of Original Loan Agreement	April 15, 2024	3b	Date of Execution of First Amendment Agreement	February 23, 2026	4	Details of amendments and impact thereof or reason for termination and impact thereof	The Board of Directors approved the First Amendment Agreement to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem, which is within the overall sanctioned financial assistance limit of Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores), at the discretion of the Company and subject to applicable approvals at a value determined in accordance with applicable law and
Sl No	Particulars	Response																		
1	Name of the Parties to the agreement	The First Amendment to the Loan Agreement is between the Company and Neoanthem.																		
2	Nature of the agreement	The First Amendment Agreement has been executed to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem.																		
3a	Date of Execution of Original Loan Agreement	April 15, 2024																		
3b	Date of Execution of First Amendment Agreement	February 23, 2026																		
4	Details of amendments and impact thereof or reason for termination and impact thereof	The Board of Directors approved the First Amendment Agreement to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only) of loan into equity shares of Neoanthem, which is within the overall sanctioned financial assistance limit of Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores), at the discretion of the Company and subject to applicable approvals at a value determined in accordance with applicable law and																		

Sr No.	Particulars	Details		
				<p>based on valuation report provided by the registered valuer at the time of allotment.</p> <p>Upon exercise of the aforesaid option, the loan exposure to the extent of Rs. 275,00,00,000/- (Rupees Two Hundred and Seventy-Five Crores Only) in the books of the Company would correspondingly be reduced and conversely its investment in Neoanthem would increase on a standalone basis. There would be no material impact on the consolidated financial statements of the Company.</p>